title: What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?
abstract: Experts and clinical guidelines recommend using long-acting injectable (LAI) antipsychotics to prevent relapse among people diagnosed with schizophrenia who do not adhere to oral antipsychotic regimens. These recommendations belie a continued lack of strong evidence that LAIs have advantages over oral medications for this purpose. Ostensibly, the failure of LAIs to demonstrate the hypothesized advantages in improving adherence and related outcomes is due to methodological problems.
authors.affiliation: Columbia University, Department of Psychiatry, 1051 Riverside Dr, New York, NY 10032 stroups@nyspi.columbia.edu.
authors.forename: T Scott
authors.initials: TS
authors.lastname: Stroup
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D015363:Quinolones / Q000008:administration & dosage*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole